JAIDS Journal of Acquired Immune Deficiency Syndromes:
Preventing HIV Infection in Women
Adimora, Adaora A. MD, MPH*,†; Ramirez, Catalina MPH*; Auerbach, Judith D. PhD‡; Aral, Sevgi O. PhD§; Hodder, Sally MD‖; Wingood, Gina PhD¶; El-Sadr, Wafaa MD, MPH#; Bukusi, Elizabeth A. MD**,††; for the HIV Prevention Trials Network Women at Risk Committee
*UNC School of Medicine, Chapel Hill, NC;
†UNC Gillings School of Global Public Health, The University of North Carolina at Chapel Hill, Chapel Hill, NC;
‡Department of Medicine, School of Medicine, University of California at San Francisco, San Francisco, CA;
§Centers for Disease Control and Prevention, Atlanta, GA;
‖New Jersey Medical School of the University of Medicine and Dentistry, Newark, NJ;
¶Rollins School of Public Health, Emory University, Atlanta, GA;
#ICAP-Columbia University, Mailman School of Public Health, Columbia University, New York, NY;
**Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya; and
††The University of Washington, Seattle, WA.
Correspondence to: Adaora A. Adimora, MD, MPH, Division of Infectious Diseases, CB# 7030, 130 Mason Farm Road, Chapel Hill, NC 27599-7030 (e-mail: firstname.lastname@example.org).
J.D.A.: has received money as consultant from San Francisco AIDS Foundation, AIDS United, NIH Office of AIDS Research, and Gilead Sciences and has received payment as a speaker from the Columbia University and the University of North Carolina. S.H.: spouse in on the board of directors of Becton Dickson; has received payment as a consultant from Gleiad Sciences, Britol-Myers Squibb, Janssen Therapeutics and Merck; has grants/grants pending with Gilead, Janssen, BMS, and Viiv GSK; through spouse has stock options with Merck and Becton Dickson. C.R.: institution has grants/grants pending with National Institutes of Health. Supported by the HIV Prevention Trials Network through the following award: UM1 AI068619.
Abstract: Although the number of new infections has declined recently, women still constitute almost half of the world's 34 million people with HIV infection, and HIV remains the leading cause of death among women of reproductive age. Prevention research has made considerable progress during the past few years in addressing the biological, behavioral, and social factors that influence women's vulnerability to HIV infection. Nevertheless, substantial work still must be performed to implement scientific advancements and to resolve many questions that remain. This article highlights some of the recent advances and persistent gaps in HIV prevention research for women and outlines key research and policy priorities.
Although the number of new HIV infections has declined, as of 2011, women constituted almost half (49%) of the world's 34 million people with HIV infection.1 Progress in reducing HIV transmission and acquisition among women is, to a great extent, the outcome of robust basic, biomedical, behavioral, and social research and the application of its findings. In this article, we highlight the key advances and gaps in these areas and point to priority areas for research and policy.
Among women, those aged 15 through 24 years are at highest risk of HIV infection,2 which remains the leading cause of death among women of reproductive age.3 Most women acquire HIV through sex with men. The distribution of HIV infection by sex varies considerably by region. In sub-Saharan Africa, women account for 59% of people with HIV, and women aged 15–24 years are 8 times more likely than men of the same age to be infected.2 In the Caribbean, young women are more than twice as likely to be infected as men. In Eastern Europe and Central Asia, where injecting drug use (IDU) and sex work are the primary drivers of the epidemic, about one third of women with HIV acquired infection by injecting drugs, and an additional 50% likely acquired infection from partners who inject drugs.2 Latin America's epidemic is predominantly concentrated among men who have sex with men, but >20% of the region's men who have sex with men also report having sex with women.2 In the United States, marked racial/ethnic disparities in HIV infection rates persist. Although the estimated number of new HIV infections among black women in the United States fell by 21% between 2008 and 2010, black women still accounted for 29% of all infections among black adolescents and adults, with rates 20 times greater than those for US white women4 and even higher incidence among some subsets of black women.5 We highlight below some of the core biological, behavioral, and social factors that individually and synergistically contribute to these HIV infection rates among women globally.
THE FEMALE REPRODUCTIVE TRACT AND RISK FOR HIV INFECTION
Research has begun to shed light on the complex interplay between the female reproductive tract, the immune system inflammatory response, and the vaginal microbiome; these interactions may either decrease or increase the tract's vulnerability to HIV infection. The mucosal immune system is unique in its need to balance the functional requirements of protecting the woman from infection while permitting survival of an allogeneic sperm and embryo.6,7 Sex hormones influence innate immunity in the tract by altering epithelial permeability, microbicide activity, and cytokine and chemokine secretion.8 The presence of certain immune cells, however, enhances the tract's vulnerability to infection. Investigators recently identified a subset of cervical Th17 CD4+ cells with multiple HIV-enhancing factors, such as CCR5, alpha4beta7, CD69, and interferon-gamma that appear to increase susceptibility to HIV.9
Increasing evidence demonstrates the role of genital tract inflammation—whether due to infection, microscopic abrasions that result from sexual activity, douching, or other causes—in increasing women's susceptibility to HIV infection.10 Seminal fluid introduced during intercourse produces an inflammatory response with induction of proinflammatory cytokines and chemokines and recruitment of leukocytes. Although these events presumably adapt the immune response to promote fertility, they could also affect response to HIV and other infections.11 Research demonstrates the importance of the vaginal microbiome in maintaining the acidic environment that protects against HIV and suggests mechanisms by which lower genital tract infections can promote HIV acquisition among women.12,13
FACTORS THAT AFFECT RISK OF TRANSMISSION TO WOMEN
Estimates of the risk of heterosexual acquisition of HIV vary widely from as low as 1 transmission per 1000 contacts between uninfected and infected individuals to 1 transmission per 3 contacts.14 Numerous factors, some of which are common in the population, likely increase women's risk and may contribute to the marked variation in these estimates of transmission. These factors include male partner characteristics, such as circumcision status and HIV viral load concentration; sexually transmitted infections (STIs), especially herpes; alterations of vaginal flora, such as bacterial vaginosis; and anal intercourse.14 Other not yet fully defined factors, such as hormonal contraception15 and reduced host susceptibility to HIV,16 may also affect HIV acquisition risk. Common sexual network patterns, such as partners' participation in concurrent sexual partnerships17 and dissortative sexual mixing by age,18 increase individual women's risk of acquiring infection and also help spread HIV throughout the population.
WOMEN AND ANAL INTERCOURSE
A substantial proportion of women report anal intercourse, and it appears that the prevalence of heterosexual anal intercourse has increased in recent years.19,20 One third of women in a national probability sample of US adults surveyed in 2002 and 2003 had ever had anal intercourse.21 The proportion of women in Britain who reported anal sex during the preceding year rose from 6.5% in 1990 to 11.3% in 2000.22 Surveys suggest significant prevalence of anal intercourse in other areas of the world as well; 18% of a sample of female sex workers (FSW) in India reported anal intercourse with a client.23 Although the increased reporting of anal intercourse may be due in part to decreased reluctance to report previously stigmatized behavior, some studies also suggest that increased access to pornography through the Internet may be a contributing factor,23–25 an observation that attests to the importance of technological advances in influencing behaviors that affect health outcomes.26
Anal intercourse not only increases efficiency of HIV transmission,14 but participation in heterosexual anal sex has been consistently associated with other risk characteristics, such as multiple and concurrent partnerships, drug or alcohol use during sex, and buying or selling sex.27,28 A result of the underrecognition of the prevalence of anal intercourse is that HIV prevention research and interventions for women have tended to focus almost exclusively on vaginal intercourse. Women are less likely to report condom use during anal intercourse than during vaginal intercourse,24,25 and some women erroneously perceive that transmission risk is lower for anal than for vaginal sex.23
CHANGING PATTERNS IN DRUG TRAFFICKING
While sexual activity remains the primary route of HIV transmission among women globally, in many settings, drug use—particularly IDU—is a substantial contributor.29 Therefore, the dynamic patterns of drug use and drug trade are relevant to global HIV prevention efforts for women and men. The prevalence of IDU is high in North America, China, Southeast Asia, Russia, Eastern and Central Europe, and Central Asia, and IDU has long been a force in the HIV epidemic in these regions.30
Considerably less is known, however, about the prevalence of IDU in Africa,30 which has emerged as a hub in cocaine and heroin trafficking as these drugs are shipped from and to destinations outside this continent.31,32 Drug trafficking can introduce drugs to residents of regions where use was previously unknown. IDU is now established in Kenya, Tanzania, Nigeria, Mauritius, and South Africa.29,30 In Mauritius, for example, IDU accounted for 73% of HIV cases in 2010, and HIV prevalence among IDUs was 47%.33 In a sample of FSW in that country, 40% reported ever having injected drugs, with respective HIV and hepatitis C virus prevalence among these women of 28.9% and 43.8%, respectively.33 IDU often results in participation in commercial sex to finance a drug habit, and conversely, sex work may lead to IDU. Thus, drug use and risky sex emerge as synergistic modes of HIV acquisition for women. Moreover, anecdotal reports note exceptionally unsafe practices, such as blood sharing,34 which exacerbate the already increased risks faced by women who inject drugs.35 Therefore, there is considerable concern about the potential for IDU to fuel HIV transmission among women and men in regions of the world where IDU had not previously been a major problem.
History of trauma, especially sexual abuse, is another significant risk factor for HIV infection among women.36,37 Gender-based violence inside and outside the context of intimate partner relationships is a common experience for women worldwide and increases their risk for HIV acquisition through several biological, behavioral, and social mechanisms: by causing genital injury as a result of forced intercourse with an infected partner; by limiting women's ability to negotiate safer sexual behaviors; and by creating a pattern of sexual risk taking among women who experienced abuse during childhood or adolescence.38 War and conflict situations especially heighten women's risk of experiencing sexual violence, including rape.39 The intersection between sexual violence, anogenital injury, and HIV infection may be a critical factor in HIV's disproportionate impact on women and girls in some regions of the world with generalized epidemics.40 Researchers have therefore recently called for a multidisciplinary focus on 3 key areas: sexual violence perpetrated against adolescent women, sexual violence in conflict-affected areas, and effects of such violence on the HIV epidemic.40
INTERVENTIONS FOR PREVENTING HIV INFECTION AMONG WOMEN
Using Antiretrovirals for HIV Prevention
Research has demonstrated that administering effective antiretroviral therapy to HIV-infected individuals can reduce sexual HIV transmission within serodiscordant partnerships by 96%.41 This finding suggests that widespread implementation of diagnosis and treatment of HIV-infected individuals (“treatment as prevention”) is likely to be a highly effective means of preventing HIV infection among both men and women. But treatment for prevention has yet to be fully implemented in any country. Moreover, because women remain at risk of acquiring HIV from partners who are unaware of their infection or who lack access to or do not wish to take antiretroviral therapy, there remains a need for effective strategies that uninfected women can use to protect themselves from HIV acquisition.
Preexposure prophylaxis (PrEP) for HIV-uninfected individuals is one such potential strategy. Five studies that included women have reported the results of trials using topical or oral tenofovir with or without emtricitabine to prevent HIV acquisition: 3 demonstrated efficacy,42–44 and 2 did not.45,46 The US Food and Drug Administration approved tenofovir/emtricitabine for use as oral PrEP in July 2012.47 These PrEP efficacy trials were conducted in countries where HIV incidence is high. A number of questions remain about women's use of PrEP, not only because of conflicting efficacy results but also because in many countries lower HIV incidence in the general population may decrease the risk/benefit ratio of long-term systemic drug use to prevent infection. For example, some studies have shown changes in bone mineral density associated with tenofovir use43,48 and higher rates of adverse effects.43,45 Moreover, exposure to tenofovir/emtricitabine and its active metabolites varies widely in different mucosal tissues, with substantially lower concentrations of tenofovir's active metabolite in vaginal and cervical tissue than in the rectum,49 suggesting that tenofovir/emtricitabine use will be less forgiving of lapses in adherence for women exposed to HIV through vaginal intercourse than for individuals whose risk of HIV infection is primarily through anal intercourse.
Despite documentation of variable adherence,45,46 PrEPs acceptability has generally been high when studied among trial participants, such as FSW in Kenya50 and women in Uganda, South Africa, and the United States.51 Other studies of hypothetical use among people not participating in trials have reported willingness to use oral PrEP among young urban African American men and women,52 although a substantial proportion (40%) of male and female emergency room patients in 2 New York City hospitals indicated that they were unlikely to use it.53 Among FSW in China, willingness to use PrEP correlated with interpersonal factors, such as level of trust in physicians.54
Focus groups among men and women in the United States revealed that interest in PrEP will likely depend on its effectiveness, cost, and ease of access.52,55 However, the best way to market PrEP to women is unclear and is likely to vary between countries and among women at risk within countries. Preferences for vaginal gel versus tablets for PrEP, for example, varied somewhat among clinical trial participants by region, with US women preferring tablets, whereas African women were divided in their preference for gel or tablets.51 The study's authors note that a potential advantage of a gel over a pill or condom is that the increased lubrication afforded by the gel may allow its promotion as a sexual health benefit that improves sex and partner satisfaction rather than simply as a disease prevention device that may raise questions of infidelity.51 Further research is needed to better define the efficacy of PrEP in women, identify new drugs for PrEP, and enhance adherence.
The excitement and enthusiasm about recent biomedical advances for HIV prevention may have diverted attention from other existing methods of prevention, such as the female condom.56 Widespread use of this method has been limited due to its cost, clinicians' and patients' lack of awareness of the existence of the product and how to obtain it, and aesthetic concerns that decreased acceptability among some users.56,57 Nevertheless, the female condom is acceptable to some women at high risk of HIV acquisition and affords several advantages.54,57 It is free of systemic side effects, protects women from STIs at least to a similar extent as male condoms,56 prevents pregnancy,58 and requires less male cooperation than the male condom. In 2005, a second-generation nitrile version of the female condom was released whose mass production is cheaper than the original polyurethane model. Studies in Brazil, South Africa, and Washington, DC, suggest that expanded distribution would be cost-effective in preventing HIV infection in those settings.59,60
Structural interventions for HIV prevention have received increasing attention in recent years—in part because of the increasing recognition that interventions that change social determinants of health have potential for the greatest population impact.61 These interventions typically attempt to change the environment in which people engage in health-related behaviors—often by enacting policy or legislation, empowering communities and groups, enabling environmental changes; shifting harmful social norms; or catalyzing social and political change.62,63 Earlier structural interventions that used community mobilization strategies and government policy initiatives have been associated with increased condom use and decreased STI rates.64–66 More recently, investigators in India used community mobilization strategies to reduce violence, harassment, stigma, and discrimination against sex workers to reduce this population's vulnerability to HIV and other STIs.67 A randomized controlled trial of cash payment for adolescent girls in Malawi for staying in school demonstrated decreased prevalence of HIV and herpes simplex virus-2 infections.68 The intervention's effect appeared to operate partly by shifting participants from older partners to younger partners with whom they had less frequent sexual activity.68 The ongoing HIV Prevention Trials Network Study 068 is evaluating the effects on HIV incidence among young women in South Africa of a cash transfer that is conditional on school attendance. Finally, the Affordable Care Act, enacted in the United States in 2010, is a structural intervention that could markedly decrease the currently large number of women and men in the United States whose lack of health insurance hinders their access to HIV prevention and treatment interventions.
Although significant progress has been made in understanding and addressing the biological, behavioral, and social factors that affect HIV infection among women, numerous research questions persist and cry out for attention; these include the need to:
1. Develop safe, effective, acceptable, and affordable methods that women can use to prevent their acquisition of HIV. These methods should require minimal adherence, be controlled by the woman, and not require a partner's cooperation.
2. Resolve the persistent questions concerning the effect of hormonal contraception—especially depot medroxyprogesterone acetate—on women's risk of acquiring and transmitting HIV.15,69–71
3. Determine how best to use rapidly changing new media and other communication technologies for prevention tasks, such as increasing medication adherence and marketing prevention products and services to women and providers.72–76
4. Identify and implement interventions that eliminate stigma and discrimination. Societies have made little headway in combating stigma, despite the longstanding recognition that stigma undermines HIV prevention efforts, and considerable gaps remain in the HIV-related stigma literature. Prevention studies should include research to define, measure, and eliminate stigma toward those living with and those at increased risk for HIV infection, such as sex workers and homosexual and bisexual men.77
5. Identify and work to change laws, policies, and other structural arrangements that increase women's vulnerability to HIV infection, such as inheritance laws and property rights violations, and educational, occupational, and income factors that drive women into sex work for economic survival.78,79
In addition, a key and pressing research question is how to determine the efficacy of interventions in settings where the HIV incidence among women is low. In many settings where HIV incidence is low, new infections are still occurring, underscoring the need for effective prevention interventions; this situation makes the conduct of clinical trials with HIV incidence outcomes difficult because the low incidence requires prohibitively large sample sizes. One potential approach is to assume that biological efficacy does not vary by country and to restrict studies in lower incidence countries to determination of safety of new interventions or the conduct of implementation studies to refine uptake, acceptability, and adherence in these settings, issues that are likely to be influenced by context and culture. Thus, it is not always reasonable to assume that a biomedical intervention that requires adherence will have the same efficacy in one cultural setting that it has in another. This situation is particularly important for women in industrialized countries, such as the United States, where a marked racial disparity exists in HIV infection rates in women in the context of overall low HIV incidence and demands the conduct of further intervention studies.
Although the recent decline in HIV incidence in some settings is encouraging, important biomedical, behavioral, and social science questions remain concerning how best to prevent HIV infection among women globally. Women need safe, effective, acceptable, accessible, and affordable methods, whose use they can control themselves without requiring a partner's cooperation. Ideally, new methods should require infrequent dosing and have minimal adherence requirements. Like contraception, women need a variety of HIV prevention methods that can be used with different partners and/or at different stages of their lives. Some methods should prevent both HIV infection and pregnancy, whereas others should prevent HIV infection without affecting ability to conceive.
Research has yielded substantial progress in preventing HIV infection among women. Further gains will require pursuing and resolving remaining research questions and fully implementing the many advances that have been made. To achieve the goal of an “AIDS-free generation,” researchers, clinicians, public health practitioners, and advocacy groups must convince the public, funders, and policy makers that continued support for HIV prevention research and implementation of effective high-impact prevention programs for women is critical.
1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Women Out Loud: How Women Living With HIV Will Help the World End AIDS. 2012; 1–98.
2. UNAIDS. Women, Girls, Gender Equality and HIV. Fact Sheet. Centers for Disease Control and Prevention 2010.
3. World Health Organization. Women's Health. Report No.: Fact Sheet No. 334. Geneva, Switzerland: World Health Organization; 2009.
4. Centers for Disease Control and Prevention. Estimated HIV Incidence in the United States, 2007-2010. HIV Surveillance Supplemental Report 2012. 2012; 17.
5. Hodder SL, et al.. HIV acquisition among women from selected areas of the United States: a cohort study. Ann Intern Med. 2013;158:10–18.
6. Wira CR, et al.. Innate immunity in the human female reproductive tract: endocrine regulation of endogenous antimicrobial protection against HIV and other sexually transmitted infections. Am J Reprod Immunol. 2011;65:196–211.
7. Dunbar B, et al.. Endocrine control of mucosal immunity in the female reproductive tract: impact of environmental disruptors. Mol Cell Endocrinol. 2012;354:85–93.
8. Wira CR, et al.. Sex hormone regulation of innate immunity in the female reproductive tract: the role of epithelial cells in balancing reproductive potential with protection against sexually transmitted pathogens. Am J Reprod Immunol. 2010;63:544–565.
9. McKinnon LR, et al.. Characterization of a human cervical CD4+ T cell subset coexpressing multiple markers of HIV susceptibility. J Immunol. 2011;187:6032–6042.
10. Roberts L, et al.. Vaginal microbicides to prevent human immunodeficiency virus infection in women: perspectives on the female genital tract, sexual maturity and mucosal inflammation. Best Pract Res Clin Obstet Gynaecol. 2012;26:441–449.
11. Sharkey DJ, et al.. Seminal fluid induces leukocyte recruitment and cytokine and chemokine mRNA expression in the human cervix after coitus. J Immunol. 2012;188:2445–2454.
12. Lai SK, et al.. Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus. J Virol. 2009;83:11196–11200.
13. Thurman AR, Doncel GF. Innate immunity and inflammatory response to Trichomonas vaginalis
and bacterial vaginosis: relationship to HIV acquisition. Am J Reprod Immunol. 2011;65:89–98.
14. Powers KA, et al.. Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis. 2008;8:553–563.
15. Heffron R, et al.. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis. 2012;12:19–26.
16. McKinnon LR, Kaul R. Quality and quantity: mucosal CD4+ T cells and HIV susceptibility. Curr Opin HIV AIDS. 2012;7:195–202.
17. Adimora AA, et al.. Heterosexually transmitted HIV infection among African Americans in North Carolina. J Acquir Immune Defic Syndr. 2006;41:616–623.
18. Gregson S, et al.. Sexual mixing patterns and sex-differentials in teenage exposure to HIV infection in rural Zimbabwe. Lancet. 2002;359:1896–1903.
19. Leichliter JS. Heterosexual anal sex: part of an expanding sexual repertoire? Sex Transm Dis. 2008;35:910–911.
20. Satterwhite CL, et al.. Changes in sexual behavior and STD prevalence among heterosexual STD clinic attendees: 1993-1995 versus 1999-2000. Sex Transm Dis. 2007;34:815–819.
21. Leichliter JS, et al.. Prevalence and correlates of heterosexual anal and oral sex in adolescents and adults in the United States. J Infect Dis. 2007;196:1852–1859.
22. Johnson AM, et al.. Sexual behaviour in Britain: partnerships, practices, and HIV risk behaviours. Lancet. 2001;358:1835–1842.
23. Tucker S, et al.. Exploring dynamics of anal sex among female sex workers in Andhra Pradesh. Indian J Sex Transm Dis. 2012;33:9–15.
24. McBride KR, Fortenberry JD, Heterosexual anal sexuality and anal sex behaviors: a review. J Sex Res. 2010;47:123–136.
25. Beattie TS, et al.. Vulnerability re-assessed: the changing face of sex work in Guntur district, Andhra Pradesh. AIDS Care. 2012.
26. Adimora AA, Schoenbach VJ. Social determinants of sexual networks, partnership formation, and sexually transmitted infections. In: Aral SO, Fenton KA, Lipshutz JA, eds. The New Public Health and STD/HIV Prevention: Personal, Public and Health Systems Approaches. New York, NY: Springer; 2013:13–32.
27. Tian LH, et al.. Heterosexual anal sex activity in the year after an STD clinic visit. Sex Transm Dis. 2008;35:905–909.
28. Gorbach PM, et al.. Anal intercourse among young heterosexuals in three sexually transmitted disease clinics in the United States. Sex Transm Dis. 2009;36:193–198.
29. Strathdee SA, Stockman JK. Epidemiology of HIV among injecting and non-injecting drug users: current trends and implications for interventions. Curr HIV/AIDS Rep. 2010;7:99–106.
30. Mathers BM, et al.. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372:1733–1745.
31. United Nations Office on Drugs and Crime. Cocaine Trafficking in Western Africa: A Situation Report. United Nations; 2007; 1–16.
32. United Nations Office on Drugs and Crime. The Opium Heroin Market: World Drug Report 2011. United Nations; 2011.
33. Johnston LG, Corceal S. Unexpectedly high injection drug use, HIV and hepatitis C prevalence among female sex workers in the Republic of Mauritius. AIDS Behav. 2013;17:574–584.
34. Dahoma MJU, et al.. HIV and substance abuse: the dual epidemics challenging Zanzibar. Afr J Drug Alcohol Stud. 2006;5:130–139.
35. El-Bassel N, Terlikbaeva A, Pinkham S, HIV and women who use drugs: double neglect, double risk. Lancet. 2010;376:312–314.
36. Wyatt GE, et al.. Does a history of trauma contribute to HIV risk for women of color? Implications for prevention and policy. Am J Public Health. 2002;92:660–665.
37. Zierler S, et al.. Adult survivors of childhood sexual abuse and subsequent risk of HIV infection. Am J Public Health. 1991;81:572–575.
38. Maman S, et al.. The intersections of HIV and violence: directions for future research and interventions. Soc Sci Med. 2000;50:459–478.
39. de Waal A, et al.. HIV/AIDS, security and conflict: new realities, new responses. S.a.C.I AIDS, ed. 2010.
40. Klot JF, et al.. Greentree white paper: sexual violence, genitoanal injury, and HIV: priorities for research, policy, and practice. AIDS Res Hum Retroviruses. 2012;28:1379–1388.
41. Cohen MS, et al.. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.
42. Abdool Karim Q, et al.. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168–1174.
43. Thigpen MC, et al.. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423–434.
44. Baeten JM, et al.. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410.
45. Van Damme L, et al.. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411–422.
46. Marrazzo J, et al.. Pre-exposure Prophylaxis for HIV in Women: Daily Tenofovir, Oral Tenofovir/Emtricitabine, or Vaginal Tenofovir Gel in the VOICE Study (MTN 003), in 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA. 2013.
47. U.S. Food and Drug Administration. FDA Approves First Drug for Reducing the Risk of Sexually Acquired HIV Infection. Department of Health and Human Services, ed. Silver Spring, MD. 2012.
48. McComsey GA, et al.. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203:1791–1801.
49. Patterson KB, et al.. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 2011;3:112re4.
50. Van der Elst EM, et al.. High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS Behav. 2012.
51. Minnis AM, et al.. Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women. AIDS Behav. 2013;17:737–747.
52. Smith DK, et al.. Attitudes and program preferences of African-American urban young adults about pre-exposure prophylaxis (PrEP). AIDS Educ Prev. 2012;24:408–421.
53. Calderon Y, et al.. HIV pre-exposure prophylaxis (PrEP)—knowledge and attitudes among a New York City emergency department patient population. Retrovirology. 2012;9(suppl 1):94.
54. Jackson T, Huang A, Chen H, Gao X, Zhang Y, Zhong X. Predictors of willingness to use HIV pre-exposure prophylaxis among female sex workers in Southwest China. AIDS Care. 2013;25:601–605.
55. Auerbach J, Banyan A, Riordan M. Will and Should Women in the U.S. Use PrEP? Findings From a Focus Group Study of At-Risk, HIV-Negative Women in Oakland, Memphis, San Diego and Washington, D.C. in XIX International AIDS Conference. Washington, DC. 2012.
56. French PP, et al.. Use-effectiveness of the female versus male condom in preventing sexually transmitted disease in women. Sex Transm Dis. 2003;30:433–439.
57. Weeks MR, et al.. Initial and sustained female condom use among low-income urban U.S. women. J Womens Health (Larchmt). 2013;22:26–36.
58. Farr G, et al.. Contraceptive efficacy and acceptability of the female condom. Am J Public Health. 1994;84:1960–1964.
59. Dowdy DW, Sweat MD, Holtgrave DR. Country-wide distribution of the nitrile female condom (FC2) in Brazil and South Africa: a cost-effectiveness analysis. AIDS. 2006;20:2091–2098.
60. Holtgrave DR, et al.. Cost-utility analysis of a female condom promotion program in Washington, DC. AIDS Behav. 2012;16:1115–1120.
61. Frieden TR. A framework for public health action: the health impact pyramid. Am J Public Health. 2010;100:590–595.
62. Auerbach J. Transforming social structures and environments to help in HIV prevention. Health Aff (Millwood). 2009;28:1655–1665.
63. Vincent R. Measuring social and structural change for HIV prevention. Paper presented at: UNAIDS Think Tank on Evaluation of HIV Prevention; 2009; Wilton Park, Sussex, United Kingdom.
64. Hanenberg RS, et al.. Impact of Thailand's HIV-control programme as indicated by the decline of sexually transmitted diseases. Lancet. 1994;344:243–245.
65. Swendeman D, et al.. Empowering sex workers in India to reduce vulnerability to HIV and sexually transmitted diseases. Soc Sci Med. 2009;69:1157–1166.
66. Kerrigan D, et al.. Environmental-structural interventions to reduce HIV/STI risk among female sex workers in the Dominican Republic. Am J Public Health. 2006;96:120–125.
67. Gurnani V, et al.. An integrated structural intervention to reduce vulnerability to HIV and sexually transmitted infections among female sex workers in Karnataka state, south India. BMC Public Health. 2011;11:755.
68. Baird SJ, et al.. Effect of a cash transfer programme for schooling on prevalence of HIV and herpes simplex type 2 in Malawi: a cluster randomised trial. Lancet. 2012;379:1320–1329.
69. Morrison CS, et al.. Hormonal contraception and the risk of HIV acquisition among women in South Africa. AIDS. 2012;26:497–504.
70. Huijbregts RP, et al.. Hormonal contraception and HIV-1 infection: medroxyprogesterone acetate suppresses innate and adaptive immune mechanisms. Endocrinology. 2013.
71. McCoy SI, et al.. Oral and injectable contraception use and risk of HIV acquisition among women in the methods for improving reproductive health in Africa (MIRA) study. AIDS. 2012.
72. Noar SM, Willoughby JF. eHealth interventions for HIV prevention. AIDS Care. 2012;24:945–952.
73. Lightfoot M, Comulada WS, Stover G. Computerized HIV preventive intervention for adolescents: indications of efficacy. Am J Public Health. 2007;97:1027–1030.
74. Juzang I, et al.. A pilot programme using mobile phones for HIV prevention. J Telemed Telecare. 2011;17:150–153.
75. Rhodes SD, et al.. A pilot intervention utilizing Internet chat rooms to prevent HIV risk behaviors among men who have sex with men. Public Health Rep. 2010;125(suppl 1):29–37.
76. Grimley DM, Hook EW 3rd. A 15-minute interactive, computerized condom use intervention with biological endpoints. Sex Transm Dis. 2009;36:73–78.
77. Mahajan AP, et al.. Stigma in the HIV/AIDS epidemic: a review of the literature and recommendations for the way forward. AIDS. 2008;22(Suppl 2):S67–S79.
78. Dworkin SL, et al.. Property rights violations as a structural driver of women's HIV risks: a qualitative study in Nyanza and Western Provinces, Kenya. Arch Sex Behav. 2012.
79. Knox A, et al.. Land Tenure, Property Rights, and HIV/AIDS: Approaches for Reducing Infection and Enhancing Economic Security, in USAID Issue Brief. US Agency for International Development; 2010.
HIV; prevention; women
© 2013 Lippincott Williams & Wilkins, Inc.
Highlight selected keywords in the article text.